Testing new agents: can we move beyond DLT?
Arceci
Robert J
RJ
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic / Q000592:standards; D004305:Dose-Response Relationship, Drug; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D020714:Maximum Tolerated Dose; D016896:Treatment Outcome
D000970:Antineoplastic Agents